PCF invests $6.3M in 31 Young Investigator Awards, supports Creativity Awards, and hosts Home Run Challenge 2026 to raise awareness. The foundation has contributed to 15 FDA-approved therapies over its 30-year history.
European guidelines now recommend lutetium-177 PSMA-617 for advanced prostate cancer, while a machine-learning model predicts treatment radiation dose. A study finds DOACs safe with modern prostate cancer drugs.
Novartis reported Phase III PSMAddition data showing Pluvicto plus standard of care cut the risk of PSA progression by 58% in PSMA-positive metastatic hormone-sensitive prostate cancer. Regulatory decisions in the United States, China and Japan are expected in the second half of 2026.
A post hoc STAMPEDE analysis found lower on-treatment PSA levels were strongly associated with improved long-term survival in advanced prostate cancer, but disease burden still affected outcomes.
PSMA-PET imaging leads to earlier use of advanced therapies like ARPIs in prostate cancer patients compared to bone scans. Real-world data on 177Lu-PSMA-617 shows comparable efficacy to the VISION trial in mCRPC patients.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
A T-cell engager drug called VIR-5500 demonstrated tumor shrinkage or growth halt in 45% of evaluable patients with advanced prostate cancer in a phase 1 trial, with 88% experiencing only mild side-effects.
Another participant with metastatic castration-resistant prostate cancer achieved undetectable PSA and negative PSMA PET after treatment with 67Cu-SAR-bisPSMA in the SECuRE trial. This marks the fifth patient to achieve undetectable disease by radiographic assessment in Clarity Pharmaceuticals' program.
The FDA has accepted Dr. Reddy's Laboratories' BLA for DRL_AB, a proposed interchangeable biosimilar to abatacept, submitted in December 2025. The application is the first for an abatacept biosimilar and is supported by Phase 1 data showing pharmacokinetic similarity.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07516223 |
MRI-Assisted Guidance for Non-Essential Tissue Sampling |
NOT_YET_RECRUITING | NA |
| NCT06872619 |
RegisterPROS - a Registry for Prostate Cancers |
ENROLLING_BY_INVITATION | |
| NCT05732441 |
Therapeutic Study of Prostatitis With Elevated PSA |
UNKNOWN | NA |
| NCT05629494 |
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test |
RECRUITING | PHASE4 |
| NCT05306314 |
Retrospective Chart Review of Treataprost Added to Antibiotic Treatment in Patients With Chronic Prostatitis |
UNKNOWN | |
| NCT04782713 |
Smart Prostate Specific Antigen (PSA) Screening Study |
COMPLETED | NA |
| NCT04393376 |
PSA Glycomics Assay for Early Detection of Prostate Cancer |
UNKNOWN | NA |
| NCT04319783 |
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04251546 |
Prediction Model fo Screening and Diagnosis of Prostate Cancer in PSA Gray Zone Based on Serum PHI Combined With TPV |
UNKNOWN | |
| NCT04240327 |
Marker Driven Selection of Patients for Prostate Biopsy and Management |
ACTIVE_NOT_RECRUITING |
